The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington's disease.

AIMS

This study evaluated the association between provider types for patients with newly diagnosed Huntington's disease (HD) and healthcare resource utilization (HCRU), costs, and treatment patterns.

MATERIALS AND METHODS

This retrospective analysis used MarketScan databases (1 January 2017-31 December 2021) to identify provider types who diagnosed and managed US adult patients with HD. Patients with continuous enrollment 6 months pre- and 12 months post-diagnosis were included. Outcomes evaluated over 12 months post-diagnosis included hospitalizations, outpatient visits, antipsychotic or vesicular monoamine transporter 2 (VMAT2) inhibitor use, and total healthcare costs.

RESULTS

Three hundred and forty eligible patients had a mean age at diagnosis of 49 years. 56.5% were female; 71.5% had a Charlson Comorbidity Index of 0. Patients were diagnosed by neurologists (48.5%), primary care providers (PCPs) (35.6%), psychiatrists (3.5%), or other providers (12.4%). Patients diagnosed by PCPs or neurologists received significantly more follow-ups by the same diagnosing provider type ( < 0.05). All-cause and HD-related outpatient visits at 12-month follow-up had more patients diagnosed by PCPs (23.9, 5.1) than neurologists (18.0, 2.4), psychiatrists (16.7, 1.67), or others (15.3, 2.4). HD-related mean costs totaled $2,489 ($1,179 inpatient and $1,310 outpatient). Patients diagnosed by neurologists had significantly lower HD-related total non-medication costs those diagnosed by PCPs (-$2,256;  < 0.05). Among patients diagnosed by neurologists PCPs, similar proportions received antipsychotics within the first year (55 52%, respectively); more patients managed by neurologists received VMAT2 inhibitors (12 7%, respectively).

LIMITATIONS

Our study includes limitations inherent to retrospective claims studies.

CONCLUSIONS

Patients with HD are most often diagnosed by neurologists or PCPs; the same diagnosing provider type typically manages follow-up. Patients diagnosed by neurologists had significantly fewer HD-related outpatient visits, lower HD-related non-drug costs, and more frequently received VMAT2 inhibitors those diagnosed by PCPs. Our findings show an integrated care team may provide evidence-based, personalized care for patients with HD.